WO2011071916A3 - Sr-bi en tant qu'indicateur de la stérilité de la femme et de la réactivité au traitement - Google Patents

Sr-bi en tant qu'indicateur de la stérilité de la femme et de la réactivité au traitement Download PDF

Info

Publication number
WO2011071916A3
WO2011071916A3 PCT/US2010/059274 US2010059274W WO2011071916A3 WO 2011071916 A3 WO2011071916 A3 WO 2011071916A3 US 2010059274 W US2010059274 W US 2010059274W WO 2011071916 A3 WO2011071916 A3 WO 2011071916A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
predictor
responsiveness
human female
female infertility
Prior art date
Application number
PCT/US2010/059274
Other languages
English (en)
Other versions
WO2011071916A2 (fr
Inventor
Annabelle Rodriguez
Original Assignee
The Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Johns Hopkins University filed Critical The Johns Hopkins University
Priority to CA2785996A priority Critical patent/CA2785996C/fr
Priority to EP10836545.3A priority patent/EP2509628B1/fr
Priority to US13/514,392 priority patent/US9163240B2/en
Priority to AU2010328295A priority patent/AU2010328295B2/en
Publication of WO2011071916A2 publication Critical patent/WO2011071916A2/fr
Publication of WO2011071916A3 publication Critical patent/WO2011071916A3/fr
Priority to US14/848,384 priority patent/US20160074417A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des méthodes de diagnostic et de traitement de maladies et de troubles liés à la synthèse de novo du cholestérol, sur la base de variants alléliques du récepteur piégeur de classe B, type I. L'invention porte en outre sur des kits d'utilisation.
PCT/US2010/059274 2009-12-07 2010-12-07 Sr-bi en tant qu'indicateur de la stérilité de la femme et de la réactivité au traitement WO2011071916A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA2785996A CA2785996C (fr) 2009-12-07 2010-12-07 Sr-bi en tant qu'indicateur de la sterilite de la femme et de la reactivite au traitement
EP10836545.3A EP2509628B1 (fr) 2009-12-07 2010-12-07 Sr-bi en tant qu'indicateur de la stérilité de la femme et de la réactivité au traitement
US13/514,392 US9163240B2 (en) 2009-12-07 2010-12-07 SR-BI mutation as a predictor of low progesterone levels and poor fetal viability during pregnancy
AU2010328295A AU2010328295B2 (en) 2009-12-07 2010-12-07 SR-BI as a predictor of human female infertility and responsiveness to treatment
US14/848,384 US20160074417A1 (en) 2009-12-07 2015-09-09 Sr-bi as a predictor of human female infertility and responsiveness to treatment

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US26141209P 2009-12-07 2009-12-07
US61/261,412 2009-12-07
US37808310P 2010-08-30 2010-08-30
US61/378,083 2010-08-30

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/514,392 A-371-Of-International US9163240B2 (en) 2009-12-07 2010-12-07 SR-BI mutation as a predictor of low progesterone levels and poor fetal viability during pregnancy
US14/848,384 Continuation US20160074417A1 (en) 2009-12-07 2015-09-09 Sr-bi as a predictor of human female infertility and responsiveness to treatment

Publications (2)

Publication Number Publication Date
WO2011071916A2 WO2011071916A2 (fr) 2011-06-16
WO2011071916A3 true WO2011071916A3 (fr) 2011-11-17

Family

ID=44146142

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/059274 WO2011071916A2 (fr) 2009-12-07 2010-12-07 Sr-bi en tant qu'indicateur de la stérilité de la femme et de la réactivité au traitement

Country Status (5)

Country Link
US (2) US9163240B2 (fr)
EP (1) EP2509628B1 (fr)
AU (1) AU2010328295B2 (fr)
CA (1) CA2785996C (fr)
WO (1) WO2011071916A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9334538B2 (en) * 2011-12-06 2016-05-10 Annabelle Rodriguez Oquendo Method for pre-screening and correlation of underlying SCARB1 gene variation to infertility in women and therapeutic use of progestational and other medications in treatment
CN116087531B (zh) * 2023-04-11 2023-06-20 北京大学第三医院（北京大学第三临床医学院） 一种卵泡膜细胞特异性标记物及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232879A1 (en) * 2002-06-07 2003-12-18 Massachusetts Institute Of Technology Lipid-altering compositions for the treatment of infertility
US20040171073A1 (en) * 2002-10-08 2004-09-02 Massachusetts Institute Of Technology Compounds for modulation of cholesterol transport
WO2009097418A2 (fr) * 2008-01-29 2009-08-06 The Johns Hopkins University Sr-bi comme prédicteur de taux élevés de lipoprotéines haute densité et de maladie cardiovasculaire

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030206887A1 (en) 1992-05-14 2003-11-06 David Morrissey RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA)
US6030778A (en) 1997-07-10 2000-02-29 Millennium Pharmaceuticals, Inc. Diagnostic assays and kits for body mass disorders associated with a polymorphism in an intron sequence of the SR-BI gene
US6228581B1 (en) * 1997-07-10 2001-05-08 Millennium Pharmaceuticals, Inc. Human intronic and polymorphic SR-BI nucleic acids and uses therefor
TW589189B (en) 1997-08-04 2004-06-01 Scras Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
EP1147204A1 (fr) 1999-01-28 2001-10-24 Medical College Of Georgia Research Institute, Inc. Composition et methode destinees a l'attenuation in vivo et in vitro de l'expression genique utilisant de l'arn double brin
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
US6844333B1 (en) * 1999-03-26 2005-01-18 The Trustees Of The University Of Pennsylvania Method of treating atherosclerosis
JP2003516124A (ja) 1999-10-15 2003-05-13 ユニバーシティー オブ マサチューセッツ 標的とした遺伝的干渉の手段としてのｒｎａ干渉経路遺伝子
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
AU2001249622B2 (en) 2000-03-30 2007-06-07 Massachusetts Institute Of Technology RNA sequence-specific mediators of RNA interference
AU2001263418A1 (en) 2000-05-23 2001-12-03 President And Fellows Of Harvard College Yeast strains to identify specific inhibitors of polo kinases
WO2001089304A1 (fr) 2000-05-23 2001-11-29 University Of Rochester Procede de preparation d'amplicons du virus de l'herpes simplex et utilisations associees
WO2001092513A1 (fr) 2000-05-30 2001-12-06 Johnson & Johnson Research Pty Limited Methodes permettant d'agir sur la suppression de gene par utilisation de facteurs renforçant l'arni
EP1309706A2 (fr) 2000-08-19 2003-05-14 Axordia Limited Modulation de la differenciation de cellules souches
WO2002029858A2 (fr) 2000-09-29 2002-04-11 Infineon Technologies North America Corp. Procede de gravure de tranchees profondes destine a reduire ou eliminer la formation de silicium noir
EP1991215A1 (fr) * 2006-03-09 2008-11-19 Cenix Bioscience GmbH Utilisation d'inhibiteurs de protéines de la classe des récepteurs éboueurs dans le traitement de maladies infectieuses
WO2008031226A1 (fr) * 2006-09-15 2008-03-20 UNIVERSITé LAVAL Marqueurs de la granulosa de la compétence de l'ovocyte mammifère à developper et leurs utilisations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232879A1 (en) * 2002-06-07 2003-12-18 Massachusetts Institute Of Technology Lipid-altering compositions for the treatment of infertility
US20040171073A1 (en) * 2002-10-08 2004-09-02 Massachusetts Institute Of Technology Compounds for modulation of cholesterol transport
WO2009097418A2 (fr) * 2008-01-29 2009-08-06 The Johns Hopkins University Sr-bi comme prédicteur de taux élevés de lipoprotéines haute densité et de maladie cardiovasculaire

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
TRIGATTI ET AL.: "The role of the high-density lipoprotein receptor SR-BI in cholesterol metabolism.", CURRENT OPINION IN LIPIDOLOGY, vol. 11, 2000, pages 123 - 131, XP008166102 *
WEST ET AL.: "Scavenger receptor class B type I protein as an independent predictor of high-density lipoprotein cholesterol levels in subjects with hyperalphalipoproteinemia.", J. CLIN. ENDOCRINOL. METAB., vol. 94, no. 4, April 2009 (2009-04-01), pages 1451 - 1457, XP055090575 *

Also Published As

Publication number Publication date
AU2010328295B2 (en) 2015-09-10
WO2011071916A2 (fr) 2011-06-16
CA2785996C (fr) 2021-04-13
US20130034539A1 (en) 2013-02-07
EP2509628B1 (fr) 2017-10-25
EP2509628A4 (fr) 2014-01-15
AU2010328295A1 (en) 2012-07-26
US20160074417A1 (en) 2016-03-17
US9163240B2 (en) 2015-10-20
EP2509628A2 (fr) 2012-10-17
CA2785996A1 (fr) 2011-06-16

Similar Documents

Publication Publication Date Title
IL260117A (en) Use of placental cells to treat diseases, syndromes or conditions of the lungs
AU2018253580A1 (en) Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
WO2008124849A3 (fr) Modulateurs de pyrrolo-pyridine kinase
WO2009126688A3 (fr) Compositions et procédés nouveaux pour le traitement de maladies de nature immunitaire
WO2008152099A3 (fr) Aryl/hétarylamides en tant que modulateurs du récepteur ep2
AU2007257423A8 (en) Purine analogs
EP2242504A4 (fr) Compositions thérapeutiques utilisées pour le traitement des affections inflammatoires oculaires
GT201000015A (es) Sulfonamidas como moduladores de trpms
WO2011014795A3 (fr) Composés et compositions pouvant servir d'inhibiteurs de la kinase syk
WO2007106236A3 (fr) Modulateurs de kinase a base de pyrrolo-pyridine
WO2011083150A3 (fr) Petites molécules pour traiter l'obésité
WO2011069063A3 (fr) Composés multicycliques et leurs procédés d'utilisation
MY178905A (en) Prevention, treatment and diagnosis of p.gingivalis infection
MX2012004078A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
PL1824384T3 (pl) System do diagnostyki zaburzeń pnia mózgu
AP2011005978A0 (en) 2, 4 diaminopyrimidines for the treatment of diseases characterised by excessive or abnormal cell proliferation.
WO2008091948A3 (fr) Protéine de liaison à la galectine-3 en tant que biomarqueur de maladie cardiovasculaire
MX2011010782A (es) Compuestos agonistas del receptor 5-ht4 para el tratamiento de trastornos cognitivos.
WO2008011484A3 (fr) Désensibilisateurs nicotiniques et procédés pour les sélectionner, les tester et les utiliser
WO2011014520A3 (fr) Composés et compositions pouvant servir de modulateurs de l'activité du gpr119
UA103197C2 (uk) Застосування ніфуртимоксу для лікування хвороб, спричинених трихомонадами
WO2011071916A3 (fr) Sr-bi en tant qu'indicateur de la stérilité de la femme et de la réactivité au traitement
WO2011084523A3 (fr) Compositions à base d'ulk1, inhibiteurs, dépistage et procédés d'utilisation
WO2009158729A3 (fr) Composés et procédés pour le diagnostic et le traitement de la maladie de chagas
WO2009014127A1 (fr) Composition pour la prévention ou le traitement d'une maladie associée à la production d'un auto-anticorps

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10836545

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 13514392

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2785996

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2010328295

Country of ref document: AU

REEP Request for entry into the european phase

Ref document number: 2010836545

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2010836545

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2010328295

Country of ref document: AU

Date of ref document: 20101207

Kind code of ref document: A